Ohkura T, Yamada S, Deguchi Y, Kimura R
Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Japan.
Biol Pharm Bull. 1999 Apr;22(4):412-7. doi: 10.1248/bpb.22.412.
The plasma concentration, total radioactivity and in vivo alpha1-adrenoceptor binding in rat tissues after intravenous (i.v.) injection of [3H]tamsulosin were measured and they were compared with those obtained after the injection of [3H]prazosin. The plasma concentration of [3H]tamsulosin was consistently higher than that of [3H]prazosin, with 1.4 times greater areas under the curve (AUC(0-infinity)) of plasma concentration. As there was a significantly lower value of apparent volume of central compartment (Vd(c)) and distribution volume at steady state (Vd(ss)) for [3H]tamsulosin than [3H]prazosin with little difference in elimination rate constant (beta), the higher concentration of [3H]tamsulosin in plasma might be associated mainly with the smaller volume of distribution. The ratio of total radioactivity in tissues to the plasma unbound concentration of [3H]tamsulosin after i.v. injection of the ligand was consistently lower than that of [3H]prazosin. These observations suggest that [3H]tamsulosin is distributed in rat tissues in a more limited manner than [3H]prazosin. A significantly lower level of in vivo specific binding of [3H]tamsulosin than [3H]prazosin was observed in the spleen, heart and liver. Further, the apparent dissociation constant (Kd) and maximal number of binding sites (Bmax) for in vivo specific [3H]tamsulosin binding were considerably lower than those for [3H]prazosin binding. Therefore, these findings suggest that [3H]tamsulosin labels preferentially a subpopulation of the alpha1-adrenoceptor sites in rat tissues labeled by [3H]prazosin. In conclusion, the present study has shown that there is a significant difference in the pharmacokinetics and in vivo alpha1-adrenoceptor binding characteristics between tamsulosin and prazosin.
静脉注射[³H]坦索罗辛后,测定了大鼠组织中的血浆浓度、总放射性及体内α1-肾上腺素能受体结合情况,并与注射[³H]哌唑嗪后的情况进行比较。[³H]坦索罗辛的血浆浓度始终高于[³H]哌唑嗪,血浆浓度曲线下面积(AUC(0-∞))大1.4倍。由于[³H]坦索罗辛的中央室表观分布容积(Vd(c))和稳态分布容积(Vd(ss))值明显低于[³H]哌唑嗪,而消除速率常数(β)差异不大,所以[³H]坦索罗辛在血浆中较高的浓度可能主要与较小的分布容积有关。静脉注射配体后,组织中总放射性与[³H]坦索罗辛血浆未结合浓度的比值始终低于[³H]哌唑嗪。这些观察结果表明,[³H]坦索罗辛在大鼠组织中的分布比[³H]哌唑嗪更有限。在脾脏、心脏和肝脏中,观察到[³H]坦索罗辛的体内特异性结合水平明显低于[³H]哌唑嗪。此外,[³H]坦索罗辛体内特异性结合的表观解离常数(Kd)和最大结合位点数(Bmax)明显低于[³H]哌唑嗪结合的相应值。因此,这些发现表明,[³H]坦索罗辛优先标记[³H]哌唑嗪标记的大鼠组织中α1-肾上腺素能受体位点的一个亚群。总之,本研究表明,坦索罗辛和哌唑嗪在药代动力学和体内α1-肾上腺素能受体结合特征方面存在显著差异。